Cross clade prophylactic and therapeutic efficacy of polyvalent equine immunoglobulin F(ab′)2 against highly pathogenic avian influenza H5N1 in mice

International Immunopharmacology

Volumn 11, Issue 12, 2011, Pages 2000-2006

  Zhao, Zhongpeng ^a   Yan, Fang ^b   Chen, Zhongwei ^a   Luo, Deyan ^a   Duan, Yueqiang ^a   Yang, Penghui ^a   Li, Zhong ^b   Peng, Daxin ^c   Liu, Xiufan ^c   Wang, Xiliang ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b SHANXI AGRICULTURAL UNIVERSITY   (China)

^c YANGZHOU UNIVERSITY   (China)

Author keywords

Equine; F(ab )2; H5N1; Infection; Mice

Indexed keywords

IMMUNOGLOBULIN F(AB')2 FRAGMENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HORSE; IMMUNIZATION; INFLUENZA VIRUS A H5N1; LETHAL DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; SURVIVAL RATE; VIRUS LOAD; WEIGHT REDUCTION;

ANIMALS; CELL LINE; HORSES; IMMUNOGLOBULIN FAB FRAGMENTS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; TREATMENT OUTCOME;

EID: 81855163384     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2011.08.011     Document Type: Article

References (36)

1. K. Subbarao, A. Klimov, J. Katz, H. Regnery, W. Lim, and H. Hall Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness Science (New York, NY) 279 1998 393 396 (Pubitemid 28063376)
2. World Health Organization (WHO). Epidemic and Pandemic Alert and Response (EPR). Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO. Available at: http://www.who.int/csr/disease/avian-influenza/ country/cases-table-2011-02-09/.
3. H. Wang, Z. Feng, Y. Shu, H. Yu, L. Zhou, and R. Zu Probable limited person-to-person transmission of highly pathogenic avian influenza A (H5N1) virus in China Lancet 371 2008 1427 1434
4. K. Ungchusak, P. Auewarakul, S.F. Dowell, R. Kitphati, W. Auwanit, and P. Puthavathana Probable person-to-person transmission of avian influenza A (H5N1) N Engl J Med 352 2005 333 340
5. Human cases of avian influenza A (H5N1) in North-West Frontier Province, Pakistan, October-November 2007 Releve epidemiologique hebdomadaire/Section d'hygiene du Secretariat de la Societe des Nations = Weekly epidemiological record/Health Section of the Secretariat of the League of Nations 83 2008 359 364
6. A.N. Abdel-Ghafar, T. Chotpitayasunondh, Z. Gao, F.G. Hayden, D.H. Nguyen, and M.D. de Jong Update on avian influenza A (H5N1) virus infection in humans N Engl J Med 358 2008 261 273
7. I. Stephenson, I. Gust, M.P. Kieny, and Y. Pervikov Development and evaluation of influenza pandemic vaccines Lancet Infect Dis 6 2006 71 72 (Pubitemid 43138904)
8. J. Wu, S.Z. Liu, S.S. Dong, X.P. Dong, W.L. Zhang, and M. Lu Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: a phase I-II randomized trial Vaccine 28 2010 6221 6227
9. J. Lin, J. Zhang, X. Dong, H. Fang, J. Chen, and N. Su Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial Lancet 368 2006 991 997 (Pubitemid 44353667)
10. J.J. Treanor, J.D. Campbell, K.M. Zangwill, T. Rowe, and M. Wolff Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine N Engl J Med 354 2006 1343 1351
11. R.C. Brady, J.J. Treanor, R.L. Atmar, W.A. Keitel, R. Edelman, and W.H. Chen Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults Vaccine 27 2009 5091 5095
12. K.M. Zangwill, J.J. Treanor, J.D. Campbell, D.L. Noah, and J. Ryea Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans J Infect Dis 197 2008 580 583 (Pubitemid 351321536)
13. A. al-Mazrou, D.W. Scheifele, T. Soong, and G. Bjornson Comparison of adverse reactions to whole-virion and split-virion influenza vaccines in hospital personnel CMAJ 145 1991 213 218
14. H.M. El Sahly, and W.A. Keitel Pandemic H5N1 influenza vaccine development: an update Expert Rev Vaccines 7 2008 241 247 (Pubitemid 351357958)
15. W. Adisasmito, P.K. Chan, N. Lee, A.F. Oner, V. Gasimov, and F. Aghayev Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a Global Patient Registry J Infect Dis 202 2010 1154 1160
16. M.D. de Jong, T.T. Tran, H.K. Truong, M.H. Vo, G.J. Smith, and V.C. Nguyen Oseltamivir resistance during treatment of influenza A (H5N1) infection N Engl J Med 353 2005 2667 2672 (Pubitemid 41817715)
17. M.T. Le, H.F. Wertheim, H.D. Nguyen, W. Taylor, P.V. Hoang, and C.D. Vuong Influenza A H5N1 clade 2.3.4 virus with a different antiviral susceptibility profile replaced clade 1 virus in humans in northern Vietnam PLoS One 3 2008 e3339
18. D.S. Fedson Confronting an influenza pandemic with inexpensive generic agents: can it be done? Lancet Infect Dis 8 2008 571 576
19. Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 52:447-56
20. H. Yu, Z. Gao, Z. Feng, Y. Shu, N. Xiang, and L. Zhou Clinical characteristics of 26 human cases of highly pathogenic avian influenza A (H5N1) virus infection in China PLoS One 3 2008 e2985
21. B. Zhou, N. Zhong, and Y. Guan Treatment with convalescent plasma for influenza A (H5N1) infection N Engl J Med 357 2007 1450 1451 (Pubitemid 47535608)
22. B.J. Hanson, A.C. Boon, A.P. Lim, A. Webb, E.E. Ooi, and R.J. Webby Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice Respir Res 7 2006 126
23. N. Prabhu, M. Prabakaran, H.T. Ho, S. Velumani, J. Qiang, and M. Goutama Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5N1 infection J Virol 83 2009 2553 2562
24. S. Maneewatch, J. Thanongsaksrikul, T. Songserm, K. Thueng-In, K. Kulkeaw, and U. Thathaisong Human single-chain antibodies that neutralize homologous and heterologous strains and clades of influenza A virus subtype H5N1 Antivir Ther 14 2009 221 230
25. Y. Chen, W. Luo, W.L. Wu, Z. Fang, L. Xia, and X. Gui Humanized antibodies with broad-spectrum neutralization to avian influenza virus H5N1 Antivir Res 87 2010 81 84
26. J. Lu, Z. Guo, X. Pan, G. Wang, D. Zhang, and Y. Li Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab′)2 in mice Respir Res 7 2006 43
27. P. Yang, Dongmei, C. Wang, C. Tang, L. Xing, and D. Luo Characterization of a highly pathogenic avian influenza H5N1 virus isolated from an ostrich Biochem Bioph Res Co 396 2010 973 977
28. X. Wang, B. Ni, X. Du, G. Zhao, W. Gao, and X. Shi Protection of mammalian cells from severe acute respiratory syndrome coronavirus infection by equine neutralizing antibody Antivir Ther 10 2005 681 690 (Pubitemid 41224960)
29. A. Wack, B.C. Baudner, A.K. Hilbert, I. Manini, S. Nuti, and S. Tavarini Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice Vaccine 26 2008 552 561
30. R.G. Webster, Y. Kawaoka, J. Taylor, R. Weinberg, and E. Paoletti Efficacy of nucleoprotein and haemagglutinin antigens expressed in fowlpox virus as vaccine for influenza in chickens Vaccine 9 1991 303 308
31. P. Yang, C. Tang, D. Luo, Z. Zhan, L. Xing, and Y. Duan Cross-clade protection against HPAI H5N1 influenza virus challenge in BALB/c mice intranasally administered adjuvant-combined influenza vaccine Vet Microbiol 146 2010 17 23
32. David Harrington Linear rank tests in survival analysis Encyclopedia of biostatistics 2005 Wiley Interscience 10.1002/0470011815.b2a11047
33. Kistner O, Crowe BA, Wodal W, Kerschbaum A, Savidis-Dacho H, Sabarth N, et al. A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models. PloS one. 5:e9349
34. T.M. Uyeki Human infection with highly pathogenic avian influenza A (H5N1) virus: review of clinical issues Clin Infect Dis 49 2009 279 290
35. J. Lang, P. Attanath, B. Quiambao, V. Singhasivanon, P. Chanthavanich, and C. Montalban Evaluation of the safety, immunogenicity, and pharmacokinetic profile of a new, highly purified, heat-treated equine rabies immunoglobulin, administered either alone or in association with a purified, Vero-cell rabies vaccine Acta Trop 70 1998 317 333 (Pubitemid 28386714)
36. J.S. Peiris, M.D. de Jong, and Y. Guan Avian influenza virus (H5N1): a threat to human health Clin Microbiol Rev 20 2007 243 267 (Pubitemid 46709304)